CLINUVEL Announces US-Focused Restructuring With Headquarters Relocation And 10%-20% Workforce Reduction

Clinuvel Pharmaceuticals shares are trading lower after the company reported weak FY26 financial results.

HP, Best Buy Dollar Tree And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

U.S. stock futures mixed, HP Inc shares fall in pre-market trading after beating earnings estimates and raising guidance. Other stocks also down.

A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

CLINUVEL Pharmaceuticals announced its tenth consecutive annual profit for FY2026 with revenues of $94.0 million and net profit after tax of $33.9 million. The company declared a $0.05 per share dividend and increased cash reserves to $252.1 million, providing financial independence to pursue expansion strategy, particularly in North America. Despite marginal revenue decline due to U.S. market competition and inventory practice changes, the company maintained disciplined expense control and achieved record SCENESSE treatment volumes.

CLINUVEL FY2026 Revenue Dips 1% To $94.0M From $95.0M, Cash Reserves Rise 12% To $252.1M Amid US Expansion Push

"CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies," said Mr Peter Vaughan, CLINUVEL’s